… lesions and long lesions are still challenging in terms of treatment success and long-term
patency. Treatment of both calcified and long lesions … to be promising to treat complex lesions. …

… PTA + BMS in complex FPA lesions, reduces restenosis and target lesion revascularization
at 12-month follow-up. Restenosis reduction is maintained irrespective of lesion length and …

… Technology and techniques of endovascular revascularization as a minimally invasive
therapy for patients with peripheral artery disease have rapidly evolved during the last decade …

… We enrolled 331 patients with symptomatic (Rutherford 2 to 4) femoropopliteal lesions up
to … primary patency, freedom from clinically driven target lesion revascularization (CD-TLR), …

… similarly detailed results on this treatment strategy in longer lesions, we herein report 12-month
data from an ongoing study that included femoropopliteal lesions longer than 15 cm. …

… the study provided objective evidence supporting the safety and … impact in the evolution
towards an ideal SFA device. … of endovascular treatment of SFA lesions in the near future. In …

… ever-increasing evolution of drug-eluting technology to further reduce in-stent restenosis
rates and increase stent patency, it may be just a matter of time until TASC C and D lesions are …

… the complexity of the stenosis and length of the lesion. Complicating the picture for self-expanding …
of rigid iliac Luminexx nitinol stents in SFA lesions averaging 45 mm in length was …

… the evolution of technology for SFA … SFA lesions and that stents or DESs will be selected
for use in patients with the worst disease morphology or those presenting with recurrent lesions. …

… too have evolved. Despite the many endovascular treatment options for femoropopliteal
lesions, … PACT SFA trial defined primary patency as freedom from binary restenosis by duplex …